HUC-3443 by Huons for Idiopathic (Essential) Hypertension: Likelihood of Approval

HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.

Ontada, Datavant Partner to Accelerate Oncology Innovation

What You Should Know: – Ontada, a McKesson business specializing in real-world data and clinical technology for community oncology, has announced a strategic collaboration with

November 12, 2024

New Sartorius Digital Handbook brings the power of advanced flow cytometry to every scientist

Sartorius, an industry-leading innovator of advanced instruments for cell analysis has released its first Advanced Flow Cytometry Handbook as a comprehensive digital guide to assays

October 26, 2023

Life science VC Vertex Ventures HC raises $200M in new fund

Vertex Ventures HC is launching its largest fund yet, with $200 million and co-led by former pharma exec Christine Brennan. Vertex Ventures HC (VVHC) said

June 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.